Biocytogen 百奥赛图
5 significant filings since 31 May 2026: 1 on litigation, 2 on guarantee or financial assistance and 1 on earnings pre-announcement, and 1 other kind. The latest, on 7 Aug 2026: 百奥赛图（北京）医药科技股份有限公司2026年半年度业绩预告的自愿性披露公告. On 7 Aug 2026 the company said it expects net profit for the period ending 30 Jun 2026 to rise by 391.87% to 412.71% from the same period a year earlier.
自 31 May 2026 起有 5 份重大公告：litigation 1 份、guarantee or financial assistance 2 份、earnings pre-announcement 1 份，另有 1 类。最新一份（7 Aug 2026）：百奥赛图（北京）医药科技股份有限公司2026年半年度业绩预告的自愿性披露公告。7 Aug 2026 公司预告截至 30 Jun 2026 的净利润较上年同期上升 391.87% 至 412.71%。
The tick on each bar marks the whole market, where 99.3% of rated reports in the same twelve months said Buy or Outperform. 刻度线为全市场水平：同期 99.3% 的评级为买入或跑赢。 Every rated report on this company said Buy or Outperform.
No broker has changed its rating on this company in the reports held.
| Broker 券商 | Analyst 分析师 | Latest Rating 最新评级 | Date 日期 | Reports 研报 | Target 目标价 |
|---|---|---|---|---|---|
| 中邮证券 | 盛丽华,徐智敏 | Buy 买入 | 2 Sep 2026 | 2 | — |
| 东莞证券 | 谢雄雄 | Outperform 增持 | 21 Apr 2026 | 1 | — |
| 信达证券 | 唐爱金,贺鑫 | Buy 买入 | 9 Jan 2026 | 1 | — |
| 华金证券 | 李蕙 | Unrated | 23 Nov 2025 | 1 | — |
Each row is a broker's latest report in the last twelve months. A price target is given in 0 of 5 reports. 每行为该券商近十二个月的最新研报；5 份中 0 份给出目标价。
Each bar counts the brokers publishing on this company in a quarter. The latest quarter is not yet complete. 每根柱为该季度发布本公司研报的券商数，最近一个季度尚未结束。